2 results
Approved WMOCompleted
To demonstrate a 25% increase of docetaxel in tumor tissue after intravenous with CriPec® docetaxel compared to Taxotere®. Additionally, systemic PK profile and adverse events will also be evaluated.
Approved WMOCompleted
Primary objectiveTo assess the safety and tolerability of intravenous 131I-IPA administered concomitantly to 2nd line XRT in recurrent GBMSecondary objectives:- To assess the maximum tolerated dose (MTD) of 131I -IPA administered concomitantly to…